Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program

With strong 1-year returns and upside potential, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program

As of December 17, 2025, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is maintaining levels near its 52-week high, following peaks at $5.95 on December 12 and 13. The investor sentiment remains heightened as the company continues to advance the Rett syndrome program.

Amid this strong share price momentum, The Fly reported that Goldman Sachs upgraded Taysha Gene Therapies, Inc. (NASDAQ:TSHA) on December 4, 2025, to “Buy” from an Early-Stage Biotech designation. Setting an $11 price target, the bank expressed optimism around TSHA-102. The firm believes the company can achieve the 33% response rate, the minimum success threshold in the REVEAL study. The metric is a significant benchmark tied to regulatory progress.

Corporate updates in the Q3 2025 results, announced on November 4, 2025, reinforced optimism. During the quarter, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) received FDA Breakthrough Therapy Designation for TSHA-102 for Rett syndrome. Furthermore, the company finalized alignment with the agency surrounding the critical REVEAL trial protocol and statistical analysis plan, with the design including a six-month interim analysis that could support a future Biologics License Application. Earlier in October, the company regained full rights to TSHA-102, enhancing its strategic flexibility.

Together, these developments portray a story of regulatory clarity, clinical momentum, and renewed market optimism.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is focused on developing gene therapy treatments for severe genetic diseases of the central nervous system. The company’s primary focus is on advancing TSHA-102 for Rett syndrome.

While we acknowledge the potential of TSHA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TSHA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and 15 Best AI Stocks to Watch in December 2025.

Disclosure: None.